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Letter to the Editor 
Clinical Chemistry
Ascorbate Oxidase Minimizes Interference by High-
Concentration Ascorbic Acid in Total Cholesterol 
Assays
Hyunjin Nah, M.D.1, Jisook Yim, M.D.1, Sang-Guk Lee, M.D.1, Jong-Baeck Lim, M.D.2, and Jeong-Ho Kim, M.D.1
Department of Laboratory Medicine1, Severance Hospital, Yonsei University College of Medicine; Department of Laboratory Medicine2, Gangnam Severance 
Hospital, Yonsei University College of Medicine, Seoul, Korea
Dear Editor,
Ascorbic acid interferes with certain clinical chemistry assays 
based on peroxidase and redox indicators [1]. Ascorbic acid is 
reported to interfere with the measurement of glucose, total 
cholesterol, triglycerides, and uric acid [2-5]. We recently en-
countered several cases of interference from ascorbic acid in 
serum total cholesterol assays based on colorimetric enzymatic 
reactions.
A 48-yr-old-female with recurrent ovarian cancer underwent 
palliative segmental resection surgery of the small intestine. The 
patient showed progressive renal impairment following surgery, 
and total cholesterol level was <3 mg/dL, as measured using the 
OSR6516 total cholesterol assay (Beckman Coulter, Brea, CA, 
USA) on an AU5800 analyzer (Beckman Coulter). We repeated 
the test with the same sample, using the Pureauto S CHO-N total 
cholesterol assay (Sekisui Medical Co., Tokyo, Japan) on a Hita-
chi7600 analyzer (Hitachi Co., Tokyo, Japan) and observed a 
concentration of 121 mg/dL. We did not repeat the OSR6516 
assay after a certain period. The specimen was checked for lipe-
mic, hemolytic, and icteric indices to rule out other possible in-
terferents. The patient was administered 30 g of ascorbic acid 
intravenously daily for 22 days prior to total cholesterol measure-
ments. Dipstick analysis of the patient’s urine was performed by 
using an URiSCAN SUPER analyzer (YD Diagnostics, Seoul, Ko-
rea), which showed a value of 2+ (equivalent to 25 mg/dL) for 
ascorbic acid. Three additional cases characterized by spuriously 
low total cholesterol values owing to ascorbic acid interference 
are summarized in Table 1. Although we could not determine 
serum ascorbic acid levels, we detected its presence by using a 
urine dipstick assay in three of the four cases.
Several studies recommend the addition of ascorbate oxidase 
to minimize ascorbic acid interference in assays to assess uric 
acid, triglyceride, oxalate, and cholesterol [5-8]. Most choles-
terol assays in clinical laboratories use an enzymatic colorimet-
ric method with the Trinder end-point reaction, in which hydro-
gen peroxide reacts with a chromogen via peroxidase to form a 
colored product; absorbance of this product is proportional to 
the concentration of total cholesterol in the sample [1]. Ascorbic 
acid interferes with peroxidase-based oxidation of the chromo-
gen [6]. Since dehydroascorbic acid is already oxidized and has 
lost its reducing power, interference via ascorbic acid can be 
successfully prevented. Commercially available total cholesterol 
assays are summarized in Table 2. Ascorbate oxidase included 
in the Sekisui total cholesterol assay effectively converts serum 
Received: July 9, 2015
Revision received: September 24, 2015
Accepted: November 4, 2015
Corresponding author: Jisook Yim
Department of Laboratory Medicine, Severance Hospital, Yonsei University 
College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-2228-2453, Fax: +82-2-364-1583
E-mail: karenwalker@yuhs.ac
© The Korean Society for Laboratory Medicine.
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Nah H, et al.
Ascorbate oxidase in total cholesterol assays
http://dx.doi.org/10.3343/alm.2016.36.2.188 www.annlabmed.org  189
ascorbic acid (up to concentrations of 50 mg/dL) to dehydro-
ascorbic acid.
Since ascorbic acid rapidly auto-oxidizes over time, it is diffi-
cult to detect its interference in cholesterol measurements [3, 
9]. Reviewing medical records can also be problematic; some 
ascorbic acid supplements are not physician-prescribed but are 
readily available over-the-counter. Furthermore, it is difficult to 
predict serum ascorbic acid concentrations based on ingested 
doses of ascorbic acid in patients with impaired renal function.
Artiss et al. [9] suggested that we can exclude ascorbate oxi-
dase in wet-chemistry reagent systems for cholesterol determi-
nation because solvated ascorbic acid is subject to air oxidation. 
Thus, the interfering substance is oxidized prior to analysis by 
laboratory instruments. This is partly true for most samples from 
patients whose renal function is intact and for those consuming 
typical ascorbic acid doses. It might be particularly problematic 
for patients with impaired renal function or for those taking high 
ascorbic acid doses. In the second case (Table 1), we presumed 
that this low cholesterol level was likely due to ascorbic acid ac-
cumulation in the blood owing to impaired renal function, even 
Table 1. Summary of the four cases with inappropriately low total cholesterol level 
Case 
No.
Age 
(yr)
Sex Diagnosis
eGFR* 
(mL/min/1.73 m2)
ascorbic acid 
supplementation 
history
Initial total 
cholesterol 
assay 
Initial serum 
total 
cholesterol 
level (mg/dL)
Subsequent total 
cholesterol assay
Subsequent 
serum total 
cholesterol level 
(mg/dL)
Urine dipstick 
analysis for 
ascorbic acid
1 48 F Ovarian 
cancer
11 30 g IV one 
   time per day for 
   22 days
Beckman Coulter/
   AU5800†
<3 (0.5 hr§) Sekisui/Hitachi 
   7600||
121 2+¶
(1.5 hr**)
2 91 M Bladder 
cancer
23 40 mg PO 4 
   times per day for 
   2 weeks
Roche/
   Cobas c701‡
<4 (6 hr§) Sekisui/Hitachi 
   7600||
94 N/A††
(N/A**)
3 89 M Diabetes 
mellitus
85 20 g IV one 
   time per day for 
   19 days
Beckman Coulter/
   AU5800†
<3 (3 hr§) Sekisui/Hitachi 
   7600||
97 2+¶
(3 days**)
4 80 M Pancreatic 
cancer
14 N/A Beckman Coulter/
   AU5800†
<3 (N/A§) Sekisui/Hitachi 
   7600||
95 3+¶
(4 hr**)
*eGFR was calculated by using 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equations currently recommended by The 
National Kidney Foundation. No patients had dialysis history; †OSR6516 Cholesterol assay (Beckman Coulter, Inc., Brea, CA, USA) on the AU5800 Clinical 
Chemistry System (Beckman Coulter, Inc.); ‡CHOL2 (Roche Diagnostics GmbH, Mannheim, Germany) assay on the Cobas c701 Analyzer (Roche 
Diagnostics GmbH); §Time interval between the most recent ascorbic acid administration and total cholesterol measurement; ||Pureauto S CHO-N (Sekisui 
Medical Co., Ltd., Tokyo, Japan) assay on the Hitachi 7600 Analyzer (Hitachi Co., Tokyo, Japan); ¶The urine dipstick analyses for cases 1, 3, and 4 were 
performed using the URiSCAN SUPER analyzer (YD Diagnostics, Seoul, Korea). In the urine dipstick analysis for ascorbic acid, -, 1+, 2+, and 3+ are 
equivalent to ascorbic acid concentrations of negative, 10 mg/dL, 25 mg/dL, and 50 mg/dL, respectively; **Time interval between total cholesterol 
measurement and urine analysis; ††Since the ascorbic acid item is not included in the CLINITEK Novus (Siemens Healthcare Diagnostics Inc., Erlangen, 
Germany) urine dipstick analysis strip, the urine ascorbic acid concentration of the patient from case 2 could not be measured.
Abbreviations: eGFR, estimated glomerular filtration rate; F, female; M, male; PO, per os or oral administration; IV, intravenously; N/A, not available.
Table 2. Summary of commercially available total cholesterol assays with respect to the presence of ascorbate oxidase
Total cholesterol assays*
Ascorbate oxidase 
in the list of ingredients 
Description of ascorbic acid interference by manufacturer
OSR6516 Cholesterol (Beckman Coulter, Inc., Brea, CA, USA) No No significant interference (within±10.0 mg/dL) up to 3 mg/dL
CHOL (Beckman Coulter, Inc., Brea, CA, USA) No No significant interference (within±10.0 mg/dL) up to 3 mg/dL
CHOL2 (Roche Diagnostics GmbH, Mannheim, Germany) No Not shown
CHOLESTEROL (Abbott Laboratories, Chicago, IL, USA) No Observed % of target: 97.6% at 3 mg/dL of ascorbic acid
Pureauto S CHO-N (Sekisui Medical Co., Ltd., Tokyo, Japan) Yes No ascorbic acid interference up to 50 mg/dL
Wako L Type CHO M (Wako Pure Chemical Industries, Ltd., Osaka, Japan) Yes No significant effects
SEIKEN T-CHO (S) (Denka Seiken Co., Ltd., Niigata, Japan) No No interference up to 50 mg/dL
Determiner C-TC (Kyowa Medex Co., Ltd., Tokyo, Japan) No May negatively affect measurement if their concentrations 
   in blood are high
*The total cholesterol assays listed are all based on colorimetric enzymatic reactions with the Trinder reaction end-point.
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though the prescribed dose of ascorbic acid was not high.
As all of our cases showed extremely low total cholesterol lev-
els, the laboratory technician easily noticed analytical errors and 
tried to troubleshoot them before reporting the results. These 
problems occurred in approximately one case bimonthly and 
were reported to managers and documented. However, interfer-
ence from low concentrations of ascorbic acid causes a small 
negative bias in total cholesterol levels, which may go unno-
ticed. Ascorbic acid is one of the most widely consumed nutri-
tional supplements, and some physicians prescribe megadoses 
for cancer therapy [10]. Consequently, managers of clinical lab-
oratories should consider the use of cholesterol assays that in-
clude ascorbate oxidase.
In conclusion, when colorimetric enzymatic assays detect in-
appropriately low levels of total cholesterol, we should suspect 
ascorbic acid interference. Addition of ascorbate oxidase to 
cholesterol reagents can minimize the inference of ascorbic 
acid in total cholesterol assays.
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